Reply to Cornely and Ullmann and to Jain and Pottinger

Clinical Infectious Diseases

Volumn 46, Issue 10, 2008, Pages 1627-1628

  Nagappan, Vijayalakshmi ^a   Deresinski, Stan ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; FLUCONAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; ITRACONAZOLE; POSACONAZOLE;

ASPERGILLOSIS; CALCULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; HUMAN; LETTER; MORTALITY; MYCOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; STOMACH PH;

EID: 43949107945     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/587756     Document Type: Letter

References (5)

1. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348-59.
2. Cornely OA, Ullmann AJ. Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death. Clin Infect Dis 2008; 46:1626-7 (in this issue).
3. Nagappan V, Deresinski S. Posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007; 45:1610-7.
4. Jain R, Pottinger P. The effect of gastric acid on the absorption of posaconazole. Clin Infect Dis 2008; 46:1627 (in this issue).
5. Noaxafil (posaconazole) oral suspension [package insert]. Kenilworth, NJ: Schering-Plough, 2006.